Insight Pharma Newsletter

You can also view this online

Dear Reader:

This month’s edition of Citeline’s newsletter, developed in alliance with the IPA, encapsulates the views of industry heads around shaping India’s innovation ecosystem & also what’s in store on deal street in 2023.

We highlight the expectations of pharma leaders & a range of global best practices as India readies policy measures to ascend the innovation value chain, while in the dealmaking arena expect mid-sized M&A, creative financing & biotech consolidation.

There’s also a stirring piece on Ukraine’s appeal to industry to restart clinical trials.

Anju Ghangurde - Executive Editor (Asia Pacific), Scrip/Pink Sheet
Dr. Shridhar Narayanan - Senior Technical Advisor - Innovation, IPA

Perspective from Industry Leaders


Whiteboarding Ideas From Novartis, Novo To Address India’s Elephants In The Room, ‘On Streets’	What Pharma CEOs, PEs Want To Move The Innovation Needle In India
Senior VPs from Novartis and Novo Nordisk offered suggestions ranging from protecting IP and fixing the perception of “elephants roaming the streets ...	Leaders of biopharma and private equity firms at a recent conference sought a robust domestic market and reimbursement mechanism to propel the innovation ...

LICENSING & COLLABORATION AGREEMENTS


Deals In 2023: Partnerships And Modest M&A	Cross-Border M&A: 10 Key Trends To Watch In 2023
Mid-sized M&A, collaborations, creative financing, and biotech consolidation will feature in 2023. IPOs and follow-ons play bit-parts ...	It will come as no surprise that cross-border M&A is impacted by the world we live in, with geopolitical tensions, rising inflation and interest rates ...

NEXT GEN: R&D


ThirtyFiveBio Makes Its Debut With First-In-Class GPR35 Antagonist Approach	Israeli Firm Wins FDA Clearance For Novel PTSD Therapy
Backed by $20m in seed funding, the UK firm is going against the grain by antagonizing, instead of agonizing ...	The US FDA has granted 510(k) clearance to GrayMatters Health for a non-invasive computer-based therapy that treats ...

CLINICAL TRIALS


Ukraine’s Plea To Industry: Restart Clinical Trials And Give Us New ‘Weapons’ To Fight Cancer	US FDA Formalizes ‘One-Trial’ Approach For Oncology Accelerated Approval
More than one year into the conflict, pharma employees in Ukraine have made heroic efforts to maintain existing clinical studies ...	Draft guidance gives recommendations for conducting one randomized controlled trial to generate the evidence for accelerated approval and confirm clinical benefit ...

Citeline Contact

Poornachandra Tejasvi .K, Senior Director - Emerging Markets, India

Mobile: +91 994 5273146
Email: poornachandra.tejasvi@informa.com

Client Services: clientservices@pharmaintel.informa.com

IPA Contact

Direct: +91 022 2610 9281
Email: info@ipa-india.org